Isis Pharmaceuticals Inc. Strikes Out on Its Own
Isis Pharmaceuticals uses its third-quarter earnings call to announce a reorganization as it pushes into late-stage development on its own.
Pharmacyclics, Inc.'s Imbruvica Holds Its Own Against Gilead Sciences, Inc.'s Zydelig
Pharmacyclics third-quarter results showed impressive sales growth for Imbruvica, a drug that competes against Gilead's Zydelig.
Why Sarepta Therapeutics Inc. Stock Imploded in October
Sarepta Therapeutics was one of the worst biotech stocks in October. Find out why its shares lost nearly one-quarter of their value and whether or not they're poised for a rebound.
Why ISIS Pharmaceuticals, Inc. Catapulted 19% Higher in October
ISIS Pharmaceuticals was among October's top performing biotech stocks. Find out why ISIS catapulted higher by 19%, as well as whether or not this run can continue.
Arena Pharmaceuticals, Inc. Earnings: Looking for More
A prescription growth rate of 30% sounds good, but Belviq has such low sales, it's hard to get too excited yet. If phase 3 trials pan out, long-term growth will likely come from use as a smoking cessation drug and as a combination product for obesity.